ArticleJournal of the American Society of Nephrology : JASN2009
Rosiglitazone is associated with mortality in chronic hemodialysis patients.
Article in Journal of the American Society of Nephrology : JASN, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 2 syntheses or guidelines pooled it, 70 citations in OpenAlex.
- Efficacy and safety of thiazolidinediones in diabetes patients with renal impairment: a systematic review and meta-analysis.Scientific reports · 2017Pooled it
- Use of instrumental variable in prescription drug research with observational data: a systematic review.Journal of clinical epidemiology · 2011Pooled it
- Thiazolidinedione use is associated with improved all-cause mortality compared with sulfonylureas among diabetic hemodialysis patients.Journal of diabetes · 2014Trial
- Machine Learning in Causal Inference: Application in Pharmacovigilance.Drug safety · 2022Review
- Diabetes mellitus in dialysis and renal transplantation.Therapeutic advances in endocrinology and metabolism · 2021Review
- Evolving concepts in the pathogenesis of uraemic cardiomyopathy.Nature reviews. Nephrology · 2019Review
- The Antidiabetic Drug Lobeglitazone Protects Mice From Lipogenesis-Induced Liver Injury via Mechanistic Target of Rapamycin Complex 1 Inhibition.Frontiers in endocrinology · 2018Article
- Current therapeutic approaches in the management of hyperglycemia in chronic renal disease.Reviews in endocrine & metabolic disorders · 2017Review
- Factors affecting outcomes in patients reaching end-stage kidney disease worldwide: differences in access to renal replacement therapy, modality use, and haemodialysis practices.Lancet (London, England) · 2016Review
- Interactions between kidney disease and diabetes: dangerous liaisons.Diabetology & metabolic syndrome · 2016Review
- Diabetes mellitus and renal failure: Prevention and management.Journal of research in medical sciences : the official journal of Isfahan University of Medical Sciences · 2015Review
- Addressing limitations in observational studies of the association between glucose-lowering medications and all-cause mortality: a review.Drug safety · 2015Review
- Observational studies of the association between glucose-lowering medications and cardiovascular outcomes: addressing methodological limitations.Diabetologia · 2014Review
- Updates on the management of diabetes in dialysis patients.Seminars in dialysis · 2014Review
- Noninsulin glucose-lowering agents for the treatment of patients on dialysis.Nature reviews. Nephrology · 2013Review
- Longer dialysis session length is associated with better intermediate outcomes and survival among patients on in-center three times per week hemodialysis: results from the Dialysis Outcomes and Practice Patterns Study (DOPPS).Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association · 2012Article
- Blood pressure levels and mortality risk among hemodialysis patients in the Dialysis Outcomes and Practice Patterns Study.Kidney international · 2012Article
- Modifiable practices associated with sudden death among hemodialysis patients in the Dialysis Outcomes and Practice Patterns Study.Clinical journal of the American Society of Nephrology : CJASN · 2012Article
- New onset diabetes after transplantation (NODAT): an overview.Diabetes, metabolic syndrome and obesity : targets and therapy · 2011Article
- Thiazolidinediones in the treatment of patients with Post-Transplant-Hyperglycemia or new-onset diabetes mellitus after renal transplantation (NODAT) - A new therapeutic option?Wiener klinische Wochenschrift · 2010Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Recent studies have associated rosiglitazone, a thiazolidinedione drug, with adverse cardiovascular outcomes in the general population with diabetes. Using data from the Dialysis Outcomes and Practice Patterns Study in the United States, we examined cardiovascular hospitalization and mortality associated with prescription of rosiglitazone, compared with other oral hypoglycemic agents, among 2393 long-term hemodialysis patients who were followed for a median of 1.1 yr. We assessed mortality risk using Cox models in patient-level and dialysis facility-level analyses that used the facility proportion of patients on rosiglitazone as the predictor (instrumental variable approach) and adjusted the models for demographics, comorbid conditions, laboratory values, and achieved dialysis dosage. Compared with patients prescribed other oral hypoglycemic agents, patients prescribed rosiglitazone had significantly higher all-cause (hazard ratio [HR] 1.38; 95% confidence interval [CI] 1.05 to 1.82) and cardiovascular (HR 1.59; 95% CI 1.14 to 2.22) mortality, and their adjusted HR for hospitalization with myocardial infarction was 3.5-fold higher (P = 0.02). We did not observe similar associations in a secondary analysis evaluating pioglitazone. By the instrumental variable approach, facilities with more than the median adjusted percentage (6.2%) of patients who had diabetes and were prescribed rosiglitazone had significantly higher all-cause mortality (HR 1.36; 95% CI 1.15 to 1.62) and cardiovascular mortality (HR 1.42; 95% CI 1.07 to 1.88) than facilities with less than the median expected percentage prescribed rosiglitazone. Our practice-based findings suggest significant associations of rosiglitazone use with higher cardiovascular and all-cause mortality among hemodialysis patients with diabetes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.